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A B ST R AC T 
 
 
Within its twisted and tight walls, where a hostile and arid environment prevails, 
the lumen of the digestive tract nests a true microuniverse called the microbiota. 
The existing relationship between humans and these microorganisms is one in 
which both benefit, creating a condition called Eubiosis.  
The dynamic relationship existing between the microbiota and the human body 
can be affected at various times, leading to an imbalance that may have 
important implications on health and generating a condition called Disbiosis. 
Recent studies have highlighted possible links between several diseases with 
incompletely elucidated etiology and disturbances of the microbiota. In this 
review we aim to analyze the existing relationship between the imbalances of the 
gastrointestinal flora and the etiopathogeny inflammatory bowel diseases, a 
group of diseases whose incidence has increased considerably in recent years. 
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There are over 100 trillion microorganisms at the level 
of the gastrointestinal tract (GI), which make up a 
complex biosystem called the microbiota. The 
composition of the microbiota is vast, containing entities 
belonging to all domains of life: Eukarya Bacteria and 
Archaea. Broadly, the main components that make up the 
structure of this microuniverse belong to the bacteria 
group and are represented by species from four major 
phyla: Actinobacteria, Proteobacteria, Bacteroidetes, and 
Firmicutes [1]. 
Between the human body and the microbiota is 
established a dynamic and very complex relationship, 
alteration of this biosystem sometimes causing adverse 
consequences on the health status. The functions of the GI 
flora depend on its composition/ biocharacteristics of the 
species, having implications for the following processes: 
modulation of the digestion process, regulation of 
immunity, biosynthesis of vitamins, and harvesting 
energy [2-6]. 
Alteration of the structure - and thus of the function- 
of the microbiota bears the name of dysbiosis, a condition 
linked to numerous pathological conditions such as type 2 
diabetes, obesity, cancer, autoimmune disorders, and 
allergies [7-13]. 
Inflammatory bowel diseases (IBD) represent a set of 
gastrointestinal disorders with incompletely elucidated 
etiology, which includes two distinct clinical and 
pathological entities: Crohn’s disease (CD) and Ulcerative 
Colitis (UC). IBD are characterized by inflammatory 
impairment of the digestive tract, which present an 
undulating evolution consisting of periods of remission 
and relapse [14]. 
Discussions 
IBD: Overview  
IBD usually refers to two chronic pathological 
conditions, represented by Crohn’s Disease and 
Ulcerative Colitis. The main feature of IBD consists of 
inflammation, which can be localized at any level of the 
digestive tract.  
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The clinical manifestations of these conditions are 
dominated by gastrointestinal symptoms, ranging from 
diarrhea to malabsorption, loss of nutrients as well as 
digestive bleeding due to inflammation. These symptoms 
are often accompanied by abdominal pain, severity 
ranging from mild to severe (life-threatening) according 
to the degree of the local/ intestinal inflammatory process. 
The inflammation has generally a chronic clinical 
evolution, marked by an alternation of remissions and 
exacerbations [15]. 
The incidence and prevalence of these diseases are 
globally increasing, the countries with the highest values 
being those that are highly developed and industrialized, 
such as North America and Northern Europe. Recent 
investigations show that the incidence is stabilising or 
slightly decreasing in developed countries, being 
conversely rapidly increasing in countries that are in the 
full process of industrialization, urbanization, and 
westernization, such as in Asia, South America, and 
Africa [16,17].  
Microbiota and IBD 
The etiology and pathophysiology of IBD are not 
completely elucidated. IBD results from the complex 
interaction of environmental and intestinal microbial 
factors within a organism that has a genetic susceptibility, 
which ultimately results in an abnormal immune response 
partly disconnected from its own regulatory mechanisms 
(Figure 1) [18].  
 
Figure 1. Interaction of factors that are contributing to 
IBD occurrence. 
Recently, more emphasis has been placed on the 
interaction between the intestinal flora and the host's 
immune system, the presence of microorganisms at 
intestinal level being a key element (if not mandatory) in the 
genesis of this pathology [19]. The loss of tolerance for 
intestinal bacteria (which triggers an immune response) may 
be one of the main explanations for pathogenesis of these 
diseases [20]. This pathological process may be strongly 
influenced by alteration in the composition, structure, and 
function of the gut microbiota, a condition referred to as 
dysbiosis. These assumptions are indirectly supported by the 
positive results (good control of intestinal inflammation) 
obtained after administration of gut flora regulators such as 
probiotics, prebiotics, and antibiotics [21].       
An important quantitative change found in the intestinal 
flora of IBD patients is reduction of the bacterial load and 
reduction of its diversity [22], the reduction of diversity 
being described within the same individual, in the same 
digestive segment, and between the areas affected by the 
inflammatory process and the healthy ones [23]. 
The main qualitative changes in the composition of the 
microbiota are represented in IBD patients by increases and 
decreases of certain bacterial populations. An important 
change in this balance is represented by an increase of the 
harmful bacteria and a reduction in the population of 
bacteria with a protective role on the digestive tract. 
The reduction of protective bacterial species is usually 
related to the following populations: gram-positive bacterias 
(species from phyla Firmicutes), butyrate-producing 
bacterias (Roseburia, Faecalibacterium prausnitzii), and 
general protective species (from the genus Bifidobacterium) 
[24, 25]. These changes are significant because all of these 
species play an important role in maintaining the intestinal 
homeostasis through a range of functions, such as: 
production of short chain fatty acids, strengthening the 
intestinal barrier, reduction of local and systemic 
inflamation, and protection from pathogenic species of 
bacteria. The protective role of these microorganisms in the 
pathophysiology of IBD is supported by multiple research 
studies. As an example, some studies have shown that 
chemically induced intestinal inflammation induces clinical 
manifestations that are more pronounced in mice with a 
sterile gut, than in conventional mice having a digestive 
tract populated with microorganisms [26]. 
The populations of harmfull bacterial species found to 
be increased in IBD patients are represented by several 
gram-negative bacteria (such as Proteobacteria, 
Pasteurellaceae) and various opportunistic pathogens 
(Escherichia coli, Fusobacteria, etc.), all these species 
having as the main characteristic a proinflammatory effect 
that is present both locally and systemically [27]. 
The manner in which the altered bacterial population 
interacts with the internal environment (leading thus to 
pathogenesis of IBD) is incompletely elucidated, but their 
presence is quite well documented. In support of this, a 
recent study proved that mice with a sterile gut do not 
develop colitis, and this is possible only through insertion of 
fecal matter containing bacteria [28]. 
Several mechanisms have been proposed to explain the 
role of an altered intestinal microbiota in the development of 
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the inflammatory process that is associated with 
inflammatory bowel diseases. Such mechanisms are 
represented by an increase in intestinal permeability leading 
to bacterial translocation, synthesis of toxic products that 
migrate into the internal environment due to increased 
intestinal permeability (generating thus endotoxinemia), 
disturbance of intestinal cell’s endoplasmic reticulum 
homeostasis, and oxidative stress. 
The increase in intestinal permeability could be a 
consequence of reduction of the population of short-chain 
fatty acid-producing bacteria. Endotoxinemia is caused by 
production of toxic substances by bacteria (such as 
Escherichia coli, Proteobacteria, Pasteurellaceae), migration 
of toxic compounds being favored by the deficient intestinal 
barrier. The functional alteration of the endoplasmic 
reticulum can be induced by different bacterial species’ 
production of various toxic substances, which enter the 
intestinal epithelial cells and are able to interfere with the 
functionality of the endoplasmic reticulum (e.g. Escherichia 
coli). Some species of bacterias (Escherichia coli, 
Helicobacter pylori) can produce reactive oxygen, causing 
oxidative stress in the digestive tract and thus contributing 
to the maintenance of the inflammatory process [29]. 
In addition to bacterial abnormalities described for IBD, 
it appears that intestinal viral and fungal populations also 
exhibit a number of alterations, even if they represent an 
extremely small part of the microbiota composition.  
Regarding the changes found in the fungal population, 
species belonging to the classes Basidiomycota, Candida 
albicans, and Ascomycota have been found to be increased, 
while the Saccharomyces cerevisiae population seems to be 
decreased. The role of the fungal implication in 
pathophysiology of IBD is incompletely elucidated, 
literature data showing that molecules present on the fungal 
wall surface (beta-glucans, chitin) are able to trigger the 
innate immune response and thus to contribute to 
maintenance of the inflammatory process [30]. 
The intestinal viral population of IBD patients is 
characterized by a greater variability, with the expansion of 
the bacteriophage-type population [31]. A recent study 
revealed an increased bacteriophages class from the order 
Caudovirales. At the level of the digestive tract, the 
bacteriophages contribute not only to the maintenance of 
bacterial homeostasis but also to the modulation of the 
immune response. Even so, there is currently not enough 
evidence to suggest that intestinal viral microbiota play an 
essential role in the development and evolution of IBD [32]. 
Highlights 
At the level of the gastrointestinal tract there are over 
100 trillion microorganisms that make up the microbiota. 
Alteration of the structure and the function of the 
microbiota, known as dysbiosis, has been linked to 
numerous pathological conditions such as type 2 diabetes, 
obesity, cancer, autoimmune disorders, and allergies. 
Inflammatory bowel diseases result from the complex 
interaction of environmental and intestinal microbial 
factors, within an organism that generally has a genetic 
susceptibility. 
The loss of tolerance for intestinal bacteria (which 
often triggers an immune response) may be one of the 
main explanations in the pathogenesis of this disease. 
Some changes encountered in composition of the 
microbiota are characterised by an increase/ abundance of 
the harmful bacteria, and a reduction in the population of 
bacteria with a protective role on the digestive tract. 
Conclusions 
IBD is a group of diseases whose incidence is still 
increasing. With multiple complications and comorbidities, 
and often debilitating clinical manifestations, IBD causes a 
marked decrease in patients’ quality of life. The etiology 
and pathogenesis of these diseases are incompletely 
elucidated, the new researches emphasizing an important 
role of the gut microbiota in the occurrence and progression 
of such inflammatory diseases. Modulation of the 
composition and structure of the commensal flora through 
multiple therapeutic pathways (like probiotics, prebiotics, 
antibiotics, and fecal transplantation) can determine 
positive results and provide a better perspective for these 
digestive conditions. 
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